DE2323906A1 - Pharmazeutisches praeparat gegen fettleibigkeit - Google Patents

Pharmazeutisches praeparat gegen fettleibigkeit

Info

Publication number
DE2323906A1
DE2323906A1 DE2323906A DE2323906A DE2323906A1 DE 2323906 A1 DE2323906 A1 DE 2323906A1 DE 2323906 A DE2323906 A DE 2323906A DE 2323906 A DE2323906 A DE 2323906A DE 2323906 A1 DE2323906 A1 DE 2323906A1
Authority
DE
Germany
Prior art keywords
fat
pharmaceutical preparations
preparations according
factor
splitting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE2323906A
Other languages
German (de)
English (en)
Inventor
Pramodkumar Premanand Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of DE2323906A1 publication Critical patent/DE2323906A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE2323906A 1972-05-11 1973-05-11 Pharmazeutisches praeparat gegen fettleibigkeit Pending DE2323906A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2210572A GB1435916A (en) 1972-05-11 1972-05-11 Pharmaceutical weight-reducing compositions

Publications (1)

Publication Number Publication Date
DE2323906A1 true DE2323906A1 (de) 1973-11-22

Family

ID=10173983

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2323906A Pending DE2323906A1 (de) 1972-05-11 1973-05-11 Pharmazeutisches praeparat gegen fettleibigkeit

Country Status (8)

Country Link
JP (1) JPS4947519A (enExample)
AU (1) AU5561973A (enExample)
BE (1) BE799141A (enExample)
DE (1) DE2323906A1 (enExample)
FR (1) FR2183979A1 (enExample)
GB (1) GB1435916A (enExample)
IL (1) IL42145A0 (enExample)
NL (1) NL7306507A (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Therapeutisches verfahren zur behandlung von hyperlipoproteinaemie und hyperlipidaemie sowie arzneimittel zu seiner durchfuehrung
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US4325956A (en) * 1978-10-20 1982-04-20 Aktiebolaget Draco Method and pharmaceutical preparation for treating chronic obstructive airway disease and cardiac disease, and intermediates for the preparation of therapeutically active xanthine derivatives
US4548818A (en) * 1978-10-20 1985-10-22 Kjellin Per G Composition and methods for the treatment of chronic obstructive airway disease and cardiac disease using 3-alkylxanthines
FR2619007A1 (fr) * 1987-08-07 1989-02-10 Dermatologiques Et Preparations cosmetiques a action lipolytique

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
EP0697020A1 (en) * 1993-05-06 1996-02-21 Merrell Pharmaceuticals Inc. 8-substituted xanthines as selective adenosine receptor agents
AT413943B (de) * 2004-03-05 2006-07-15 Lohninger Alfred Dr L-carnitin enthaltende, oral verabreichbare zusammensetzung
GB2457710A (en) * 2008-02-25 2009-08-26 Andrew Nicolaou Thyroxine and its use in weight loss and obesity treatment

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Therapeutisches verfahren zur behandlung von hyperlipoproteinaemie und hyperlipidaemie sowie arzneimittel zu seiner durchfuehrung
US4325956A (en) * 1978-10-20 1982-04-20 Aktiebolaget Draco Method and pharmaceutical preparation for treating chronic obstructive airway disease and cardiac disease, and intermediates for the preparation of therapeutically active xanthine derivatives
US4548818A (en) * 1978-10-20 1985-10-22 Kjellin Per G Composition and methods for the treatment of chronic obstructive airway disease and cardiac disease using 3-alkylxanthines
US4644001A (en) * 1978-10-20 1987-02-17 Aktiebolaget Draco 3-Alkylxanthines, composition and methods for the treatment of chronic obstructive-airway disease and cardiac disease
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
EP0046167B1 (de) * 1980-07-11 1984-12-12 LEOPOLD PHARMA GESELLSCHAFT m.b.H. Nährlösung für die vollständige parenterale Ernährung und für gesteigerte Energieproduktion und Verfahren zu deren Herstellung
FR2619007A1 (fr) * 1987-08-07 1989-02-10 Dermatologiques Et Preparations cosmetiques a action lipolytique

Also Published As

Publication number Publication date
AU5561973A (en) 1974-11-14
FR2183979A1 (enExample) 1973-12-21
GB1435916A (en) 1976-05-19
IL42145A0 (en) 1973-06-29
JPS4947519A (enExample) 1974-05-08
BE799141A (fr) 1973-11-05
NL7306507A (enExample) 1973-11-13

Similar Documents

Publication Publication Date Title
DE69219136T2 (de) Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
DE69533940T2 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE69624580T2 (de) Verfahren und zusammensetzung zur verbesserten parenteralen ernährung
DE69304118T2 (de) Zusammensetzung aus Omega-3 Fettsäuren enthaltendem Material und einem Glutathionstimulator zur Behandlung von Immunkrankheiten und viralen Infektionen
DE2556100C2 (enExample)
DE69121561T2 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE3211587A1 (de) Verwendung einer therapeutischen mischung zur regulierung des koerpergewichtes von menschen und saeugetieren
DE4035456A1 (de) Arzneimittel, welche als wirkstoff schwefel enthaltende carbonsaeuren enthalten sowie deren verwendung zur bekaempfung von retroviren
DE2935709A1 (de) Aminosaeureloesungen und deren verwendung
AT408414B (de) Pharmazeutische kompositionen zum vorbeugen und heilen von krebserkrankungen und verfahren zu ihrer herstellung
EP0046167A1 (de) Nährlösung für die vollständige parenterale Ernährung und für gesteigerte Energieproduktion und Verfahren zu deren Herstellung
DE3883743T2 (de) Aminosäuren, nützlich bei Leberstörungen.
DE3137125C2 (enExample)
Fitch et al. Vitamin E Deficiency in the Monkey: V. Estimated Requirements and the Influence of Fat Deficiency and Antioxidants on the Syndrome
DE69331465T2 (de) Intravenöse lösung, die den protein - und wasserverlust im körper reduziert
DE2323906A1 (de) Pharmazeutisches praeparat gegen fettleibigkeit
DE3040780C2 (de) Verwendung einer pharmazeutischen Zusammensetzung zur Behandlung von Diabetes
DE2921852A1 (de) Lipide senkendes mittel
EP0185210A2 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE60038174T2 (de) Nahrungszusammensetzung zur regulierung des körpergewichts
DE60124769T2 (de) Nahrungsergänzung mit schlankheitseffekt
DE60032509T2 (de) Chrom-histidin-komplexe als nahrungsmittelzusätze
DE2750159C3 (de) Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung
DE3739700A1 (de) Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin
DE60220799T2 (de) Hypoglykämisches mittel